MedTrace Logo

AllerPops Reduce Nasal Symptoms in Adult Volunteers With Allergic Rhinitis

NCT05956691 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-07-24

No results posted yet for this study

Summary

The goal of this clinical trial is to test AllerPops' effectiveness in people who suffer from allergic rhinitis. The main question\[s\]it aims to answer are:

1. To assess the effectiveness of AllerPops on relieving nasal symptoms compared to the control group in volunteers with seasonal/year-long allergies during the first 7 days of the 21-day intervention period.
2. To evaluate the safety of AllerPops administration in volunteers with seasonal/year-long allergies during a 21-day intervention period.

Up to 30 days between Screening (V1) and Baseline (V2), and a 21-day intervention period, with dosing occurring every other day for a minimum of 3 doses, and thereafter until the participant is satisfied with the relief of the nasal allergy symptoms. The suitable season for the trial will be determined based on the seasonal variation measures.

Researchers will compare slow and fast consuming groups to see if the way of use impact the effectiveness.

Conditions

  • Allergic Rhinitis

Interventions

DIETARY_SUPPLEMENT

AllerPops

Take AllerPops once every other day, as instructed, for a minimum of 3 doses. After each dose, wait at least 30 minutes before eating your next meal. After the 3rd dose, you may continue every other day until you are satisfied with the symptom relief up to and including Day 13.

Sponsors & Collaborators

  • AllerPops Corp

    lead INDUSTRY

Principal Investigators

  • Raj Gurinder, MD · Independent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-05
Primary Completion
2022-09-05
Completion
2022-09-21

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05956691 on ClinicalTrials.gov